Deetta Debault
Gerontology · Fort Myers, FLNPI 1477960888
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 758 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 9.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $4,534 and has fallen 68.0% since, to $1,453 in 2025. Among gerontology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 758 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$1K
- Novo Nordisk$1K
- AstraZeneca$990
- Merck$829
- Pfizer$578
- plus $8K from 54 others
What the payments were for
- Food & beverage$14,280100%
- Education$480%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$229
- BREZTRI$124
- VRAYLAR$122
- TRELEGY ELLIPTA$105
How this compares
$14,328 in reported general payments places this provider in the 95th percentile of 714 gerontology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $106,997 |
| MounjaroTirzepatide | 72 | $86,149 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $69,469 |
| EliquisApixaban | 79 | $68,628 |
| JardianceEmpagliflozin | 52 | $59,474 |
| FarxigaDapagliflozin Propanediol | 41 | $44,245 |
| TrulicityDulaglutide | 30 | $38,424 |
| XareltoRivaroxaban | 40 | $33,220 |
| Repatha SureclickEvolocumab | 30 | $27,049 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $27,047 |
| GemtesaVibegron | 26 | $26,842 |
| EntrestoSacubitril/Valsartan | 23 | $25,299 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $21,534 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $17,873 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $14,832 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $518 | $124,574102 claims |
| Novo NordiskOzempic | $1,006 | $106,99777 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,183 | $94,674116 claims |
| PfizerEliquis | $578 | $68,62879 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $990 | $62,36884 claims |
| Boehringer IngelheimJardiance | $111 | $59,47452 claims |
| Johnson & JohnsonXarelto | $368 | $33,22040 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $353 | $27,04715 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $248 | $26,84226 claims |
| NovartisEntresto | $557 | $25,29923 claims |
| MerckJanumet, Januvia | $829 | $22,53623 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $185 | $13,77118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 714 gerontology providers in Florida.
Other gerontology in Fort Myers
- Heidi PapeshFort Myers$9K
- Johnny IqbalFort Myers$8K
- Francesca BarberaFort Myers$5K
- Flavius NascimentoCoral Springs$226K
- Michelle HartogWinter Park$90K
- Alejandra Rosales-CohenOrange City$88K
- Jennifer PacilettiAtlantis$66K
- Tatiana ClarkBradenton$34K
- Brandi LigonWinter Park$27K
- Boni MayOrlando$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.